Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK-Enigma flu test deal

This article was originally published in The Gray Sheet

Executive Summary

GlaxoSmithKline and Salisbury, U.K.-based Enigma Diagnostics are partnering to supply the first point-of-care influenza tests to identify specific flu virus strains, the firms announce July 21. The tests, based on the Enigma ML (mini laboratory) real-time polymerase chain reaction technology platform, will provide fully-automated results from swab samples in less than an hour, with the same accuracy standards as reference laboratory tests that take several days, according to GSK. A European trial of working prototypes of the Enigma ML tests will begin in the fourth quarter of this year, according to the company
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT027710

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel